Amarillo Biosciences Licenses Low Dose Oral Interferon to Global Kinetics for Sale in Three Countries in SE Asia
Avian Flu Fuels Interest in Low Dose Oral Interferon as Potential Therapy
Amarillo Biosciences, Inc. (ABI) announced that it had entered into a licensing and supply agreement with Seattle-based Global Kinetics, Inc. to provide low dose oral interferon for sale in Cambodia, Laos and Vietnam.
Interest in the Company's low dose oral interferon has risen with international concern about the potential of the current bird flu outbreak to develop into a pandemic. Health care professionals agree that the public is vulnerable to the pending influenza pandemic. Effective vaccination for influenza is the goal of health officials. However, no vaccine is yet available for the H5N1 virus (bird flu), and the therapies that do exist, such as Tamiflu, are in limited supply worldwide. Consequently, ABI and Global Kinetics are working together to bring a promising new prevention and treatment option for influenza to the developing world. Global Kinetics intends to market ABI's low dose oral interferon through a Cambodian company (Global Kinetics of Cambodia). "
Other news from the department business & finance
